Literature DB >> 9602327

CD44 variant expression in inflammatory colonic mucosa is not disease specific but associated with increased crypt cell proliferation.

G Fromont Hankard1, J P Cezard, Y Aigrain, J Navarro, M Peuchmaur.   

Abstract

AIMS: A recent study reported increased epithelial expression of CD44 variants in ulcerative colitis (UC) compared with Crohn's disease (CD). However, the use of CD44 expression for diagnostic purposes in inflammatory bowel disease has been controversial, and the meaning of the appearance of CD44 variants in epithelial colonic cells remains unknown. We investigated the relationship between CD44 isoform expression and crypt cell proliferation in paediatric colitis. METHODS AND
RESULTS: The expression of CD44v3, CD44v6, and MIB1 (proliferation marker) was studied by immunohistochemistry on surgical colonic samples of UC (n = 13), CD (n = 10), colostomy resections with non-specific mucosal inflammation (NSMI) (n = 3), and normal controls (N = 5). The proliferation index (% of MIB1 positive cells) was assessed in both v6 positive and v6 negative crypts. Epithelial expression of CD44v3 and v6, negative in normal controls, was variable and focal in colitis. No preferential expression of CD44 variants was found in UC. The proliferation index was dramatically increased in v6 positive crypts compared with v6 negative crypts in UC, CD and NSMI.
CONCLUSIONS: These data suggest that CD44 variant staining is not a useful marker for distinguishing paediatric UC from CD, and that CD44v6 expression in the inflamed colonic mucosa is not disease specific but is related to crypt cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9602327     DOI: 10.1046/j.1365-2559.1998.00404.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  9 in total

1.  The distribution of extracellular matrix proteins and CD44S expression in human astrocytomas.

Authors:  B Oz; F A Karayel; N L Gazio; F Ozlen; K Balci
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

2.  Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis.

Authors:  Bo Xiao; Zhigang Xu; Emilie Viennois; Yuchen Zhang; Zhan Zhang; Mingzhen Zhang; Moon Kwon Han; Yuejun Kang; Didier Merlin
Journal:  Mol Ther       Date:  2017-01-28       Impact factor: 11.454

Review 3.  Oral nanomedicine for modulating immunity, intestinal barrier functions, and gut microbiome.

Authors:  Yonghyun Lee; Nobuhiko Kamada; James J Moon
Journal:  Adv Drug Deliv Rev       Date:  2021-10-26       Impact factor: 15.470

Review 4.  Novel drug delivery systems for inflammatory bowel disease.

Authors:  Farah Yasmin; Hala Najeeb; Shehryar Shaikh; Muhammad Hasanain; Unaiza Naeem; Abdul Moeed; Thoyaja Koritala; Syedadeel Hasan; Salim Surani
Journal:  World J Gastroenterol       Date:  2022-05-14       Impact factor: 5.374

5.  Combination Therapy for Ulcerative Colitis: Orally Targeted Nanoparticles Prevent Mucosal Damage and Relieve Inflammation.

Authors:  Bo Xiao; Zhan Zhang; Emilie Viennois; Yuejun Kang; Mingzhen Zhang; Moon Kwon Han; Jiucun Chen; Didier Merlin
Journal:  Theranostics       Date:  2016-09-25       Impact factor: 11.556

6.  Modulation of Gut Barrier Functions in Ulcerative Colitis by Hyaluronic Acid System.

Authors:  Niranjan G Kotla; Isma Liza Mohd Isa; Swetha Rasala; Secil Demir; Rajbir Singh; Becca V Baby; Samantha K Swamy; Peter Dockery; Venkatakrishna R Jala; Yury Rochev; Abhay Pandit
Journal:  Adv Sci (Weinh)       Date:  2021-11-10       Impact factor: 16.806

7.  Hyperbaric oxygen therapy stimulates colonic stem cells and induces mucosal healing in patients with refractory ulcerative colitis: a prospective case series.

Authors:  Mohamed Bekheit; Nahed Baddour; Khaled Katri; Yousry Taher; Khaled El Tobgy; Essam Mousa
Journal:  BMJ Open Gastroenterol       Date:  2016-04-28

Review 8.  New Insights of Oral Colonic Drug Delivery Systems for Inflammatory Bowel Disease Therapy.

Authors:  Adrian H Teruel; Isabel Gonzalez-Alvarez; Marival Bermejo; Virginia Merino; Maria Dolores Marcos; Felix Sancenon; Marta Gonzalez-Alvarez; Ramon Martinez-Mañez
Journal:  Int J Mol Sci       Date:  2020-09-05       Impact factor: 5.923

Review 9.  Exploitation of Marine-Derived Robust Biological Molecules to Manage Inflammatory Bowel Disease.

Authors:  Muhammad Bilal; Leonardo Vieira Nunes; Marco Thúlio Saviatto Duarte; Luiz Fernando Romanholo Ferreira; Renato Nery Soriano; Hafiz M N Iqbal
Journal:  Mar Drugs       Date:  2021-03-30       Impact factor: 5.118

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.